# Yuanta Investment

> Yuanta Investment is a VC fund backing Biotechnology and Pharmaceutical. See 59 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Seoul, South Korea
- Total investments: 59
- Last investment: Jul 2026
- Lead investor: 10%
- Last updated: Aug 2026
- Website: http://www.yuantainvest.com/

Yuanta Investment is a VC fund in Seoul focused on Biotechnology and Pharmaceutical. A star of private equity market grow up your companies and ascend your potential.

## Contacts

5 contacts available for Yuanta Investment. Shizune tracks 3 team members at Yuanta Investment. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/yuanta-investment?utm_source=investor_profile

## Round sizes

| Stage | Round size |
| --- | --- |
| Series A | $5.6M–$57M |
| Series B | $3.5M–$54M |
| Series C | $12M–$45M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 16 | 27% |
| Pharmaceutical | 13 | 22% |
| Medical | 9 | 15% |
| Health Care | 7 | 12% |
| Information Technology | 7 | 12% |

93 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 21 | 36% |
| Series A | 13 | 22% |
| Series C | 12 | 20% |
| Seed | 3 | 5% |
| Funding Round | 3 | 5% |

9 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| South Korea | 45 | 76% |
| United States | 3 | 5% |
| Taiwan | 1 | 2% |
| Vietnam | 1 | 2% |
| Indonesia | 1 | 2% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| KiSuk Yang | Vice Chairman | 0 | https://shizune.co/investors/profile/kisuk-yang |
| SangWoon Hwang | CEO | 1 | https://shizune.co/investors/profile/sangwoon-hwang |
| Park Sang-hyun | Director | 1 | https://shizune.co/investors/profile/park-sang-hyun |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| ArcGen Bioscience | ArcGen Bioscience is a biopharmaceutical development company focused on researching, developing, and advancing innovative therapeutic solutions to address unmet medical needs through cutting-edge biotechnology and drug development. | $6.7M | Series A | Jul 13, 2026 |  |
| MOAIS | MOAIS develops a smartphone AI solution that analyzes golf swing problem and offers a lesson solution. It is an on-device AI optimized for smart phones, has a video pose estimation, video segmentation, video classification, video object detection, and image processing of golf swing video. | $3.7M | Series B | Apr 30, 2026 |  |
| XYZ | XYZ is an retail-tech startup that develops AI-based service robots and automation systems designed for use in commercial and everyday environments. The company builds robotic technologies that integrate hardware, software, and digital interfaces to automate tasks in areas such as food preparation, retail operations, and building services. Itssolutions combine robotics, artificial intelligence, and connected platforms to support unmanned or semi-automated service experiences within physical spaces. The company offers robotic systems that perform tasks such as automated beverage preparation, self-service food production, and customer interaction within retail or hospitality environments. These systems can integrate with mobile ordering, digital payment, and pickup workflows, enabling automated service processes from ordering to product delivery. The robots are designed to operate continuously while managing repetitive operational tasks typically performed by human staff.XYZ also develops building-level automation solutions that use delivery robots capable of navigating multiple floors and indoor spaces. Through a robot building solution platform, the company connects robots with building infrastructure and digital management systems to enable services such as in-building delivery and automated logistics. These systems allow operators to manage robots and service workflows across large indoor facilities. | $8.7M | Series B | Mar 09, 2026 |  |
| BreezeBio | GenEdit was founded to transform the delivery of gene therapies and enable the next generation of non-viral, gene editing-based therapeutics. GenEdit’s proprietary technology, NanoGalaxy™ platform solves current delivery challenges by systematically screening its nanoparticle library and providing safer and efficient delivery to target tissues. Thecompany's tool makes therapeutic gene editing possible and is easier to use, faster and more accurate than previous gene-editing techniques and thus has the potential for a wide range of therapeutic applications, enabling physicians to cure incurable genetic diseases. | $60M | Series B | Feb 25, 2026 |  |
| Galux | Galux provides molecular design technology focusing on discovering and developing novel drugs for incurable and rare diseases using its AI-based drug design platform technologies. | $29M | Series B | Feb 09, 2026 |  |
| MediMabBio | MediMabBio platform uses systems biology combined with sophisticated immunological solutions to identify significantly improving immuno-oncology drugs that can actively target a range of solid tumors. The antibody discovery I-O platform brings the advantages of rational drug design to large molecule therapeutic development. | $17.8M | Series B | Oct 24, 2025 |  |
| Newracle Genetics | Newracle Genetics is a bio venture company that develops gene therapy products for neurological diseases. | $18.8M | Series C | Sep 08, 2025 |  |
| Nex Eye | Nex Eye is an innovative biotechnology firm that offers revolutionary immunotherapy solutions for individuals battling cancer. The company addresses the fundamental reasons behind the failure of immunotherapy, which are influenced by the biology of cancer itself. Utilizing its ON-SMRT® platform based on actual patient data and resistant cancermodels, Nex Eye identifies new immune-evasion targets such as ONCOKINE®. By transforming the approach to tackling immune resistance, the firm is pioneering a new era in cancer therapy by revitalizing the capabilities of the immune system. | $44.2M | Series B | Aug 13, 2025 |  |
| Esol | Esol operates a semiconductor equipment business focused on extreme ultraviolet (EUV) technology. It provides EUV pellicle transmittance and mask phase measurement systems, as well as interference patterning equipment, enabling higher-resolution, denser, and more advanced semiconductor chips. | $54.3M | Series B | Jul 06, 2025 |  |
| BSP | BSP is a semiconductor company. It specializes in laser technology. The company supplies equipment and materials applicable to various industrial fields, including semiconductor packaging, FPD, mini & micro LED, automotive, and solar cells. The company is involved in the manufacture of semiconductor and LED products. | $737.8K | Series A | Jun 09, 2025 |  |

10 of 59 investments shown.

## Co-investors
- [Korea Investment Partners](https://shizune.co/investors/profile/korea-investment-partners) — VC Fund, 9 deals together
- [Korea Development Bank](https://shizune.co/investors/profile/korean-development-bank) — VC Fund, 9 deals together
- [Industrial Bank of Korea](https://shizune.co/investors/profile/industrial-bank-of-korea) — VC Fund, 7 deals together
- [KB Investment](https://shizune.co/investors/profile/kbinvest) — VC Fund, 7 deals together
- [Daekyo Investment](https://shizune.co/investors/profile/daekyo-investment-0481) — VC Fund, 6 deals together
- [Korea Development Bank](https://shizune.co/investors/profile/kdb-industrial-bank) — VC Fund, 5 deals together

## Similar investors

### Similar industry
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [SV Angel](https://shizune.co/investors/profile/sv-angel) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

### Similar country
- [National Development Fund of Taiwan Government](https://shizune.co/investors/profile/national-development-fund-of-taiwan-government) — VC Fund
- [Darwin Venture Management](https://shizune.co/investors/profile/darwin-venture-management) — VC Fund
- [AVA Angels](https://shizune.co/investors/profile/ava-angels) — VC Fund

## Featured in investor lists
- [Biotechnology Investors in South Korea](https://shizune.co/investors/biotechnology-investors-south-korea)
- [Biotechnology VC Funds in South Korea](https://shizune.co/investors/biotechnology-vc-funds-south-korea)
- [Biotech Investors in South Korea](https://shizune.co/investors/biotech-investors-south-korea)
- [Biotech VC Funds in South Korea](https://shizune.co/investors/biotech-vc-funds-south-korea)
- [Mobile Investors in Taiwan](https://shizune.co/investors/mobile-investors-taiwan)
- [Mobile VC Funds in Taiwan](https://shizune.co/investors/mobile-vc-funds-taiwan)

## FAQ

### What does Yuanta Investment invest in?

Yuanta Investment invests primarily in Biotechnology, Pharmaceutical and Medical startups, most often at Series B and Series A stage. Most of the 59 investments tracked by Shizune back companies in South Korea. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is Yuanta Investment's check size?

Yuanta Investment typically joins rounds of $5.6M–$57M at Series A, $3.5M–$54M at Series B and $12M–$45M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Yuanta Investment participates in.

### How do I contact Yuanta Investment?

Public channels for Yuanta Investment include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Yuanta Investment?

The team at Yuanta Investment includes KiSuk Yang (Vice Chairman), SangWoon Hwang (CEO) and Park Sang-hyun (Director). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co